Abstract
Denosumab is a monoclonal antibody against the receptor activator of nuclear factor kappa B ligand (RANKL), and it is considered one of the antiresorptive therapies used in metastatic bone lesions from solid tumors to prevent skeletal-related events (SREs). Although hypocalcemia is a recognized side effect of Denosumab, we are presenting a case of metastatic small cell lung cancer (mSCLC) with severe resistant hypocalcemia and hypophosphatemia after receiving a single dose of Denosumab for SREs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
